TY - JOUR
T1 - Genitourinary Cancer
T2 - Updates on Treatments and Their Impact on the Kidney
AU - Orozco Scott, Paloma
AU - Deshpande, Priya
AU - Abramson, Matthew
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2022/11
Y1 - 2022/11
N2 - Genitourinary cancers are diverse in their presentation, prevalence, and mortality risk. Although there have been significant advancements in medical (eg, immune checkpoint inhibitors and tyrosine kinase inhibitors) and surgical treatments of genitourinary cancers, patients are still at risk for chronic kidney disease, hypertension, and electrolyte derangements in the short and long term. In addition, pre-existing kidney disease may increase the risk of developing some genitourinary cancers. This review focuses on the kidney-related effects of treatments for renal cell carcinoma and bladder and prostate cancers.
AB - Genitourinary cancers are diverse in their presentation, prevalence, and mortality risk. Although there have been significant advancements in medical (eg, immune checkpoint inhibitors and tyrosine kinase inhibitors) and surgical treatments of genitourinary cancers, patients are still at risk for chronic kidney disease, hypertension, and electrolyte derangements in the short and long term. In addition, pre-existing kidney disease may increase the risk of developing some genitourinary cancers. This review focuses on the kidney-related effects of treatments for renal cell carcinoma and bladder and prostate cancers.
KW - Genitourinary cancer
KW - bladder
KW - immune checkpoint inhibitor
KW - kidney
KW - prostate
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85158909388&partnerID=8YFLogxK
U2 - 10.1016/j.semnephrol.2023.151344
DO - 10.1016/j.semnephrol.2023.151344
M3 - Review article
AN - SCOPUS:85158909388
SN - 0270-9295
VL - 42
JO - Seminars in Nephrology
JF - Seminars in Nephrology
IS - 6
M1 - 151344
ER -